A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients

7510 Background: The JBR.10 trial demonstrated a significant survival benefit from adjuvant chemotherapy in stage IB-II NSCLC patients (HR 0.69, p=0.04). However, a significant interaction with sta...